No somos una agencia de publicidad, no somos creativos ni diseñadores. No somos estrategas ni programadores. Somos solucionadores de problemas de comunicación y no nos importa en qué medio haya que hacerlo.
Somos dimensión.
Somos dimensión.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $95M
Founded date: 2013
Investors 1
| Date | Name | Website |
| - | New Leaf V... | nlvpartner... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 21.04.2015 | Series B | $65M | - |
| 23.06.2014 | - | $30M | - |
Mentions in press and media 9
| Date | Title | Description |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 14.09.2015 | Gene therapy startup Dimension Therapeutics files for $115M IPO | Several biotech startups are using hemophilia as an early target for gene therapy. Dimension plans to launch Phase 1/2 trials for its hemophilia B candidate, DTX101, as well as launch IND-enabling studies for its hemophilia A therapy, by th... |
| 21.04.2015 | Dimension Therapeutics Completes $65M Series B Financing | Dimension Therapeutics, Inc., a Cambridge, MA-based rare disease company advancing novel, liver-directed treatments for diverse genetic disorders, completed a $65m Series B financing. The round was led by new investor New Leaf Venture Partn... |
| 22.01.2015 | Regenxbio nets $30M to bring its gene therapy to clinical trial | Here’s how it works: In Hurler syndrome, for instance, children don’t carry a gene that develops an enzyme called IDUA that breaks down complex sugars. These build up, and ultimately impair mental development, organ function, physical abili... |
| 23.06.2014 | Dimension Therapeutics Closes $30M Financing | Dimension Therapeutics, a Cambridge, MA-based gene therapy company focused on developing novel treatments for rare diseases, closed a $30m financing. New investor OrbiMed joined existing investor Fidelity Biosciences in the round. Launched ... |
| 20.11.2013 | Gene therapy startup launches with $5M and eyes toward a better treatment for hemophilia | Currently Dimension is working on IND-enabling studies of a drug candidate for hemophilia B, a hereditary bleeding disorder characterized by a lack of one of the proteins needed to form blood clots in the body. It can cause a person to expe... |
| - | Regenxbio nets $30M to bring its gene therapy to clinical trial | Washington, D.C.-based gene therapy outfit Regenxbio just raised $30 million to bring its platform into the clinic. The dollars will help Regenxbio generate clinical proof of concept data, as well as work toward in-licensing new programs. T... |
| - | Gene therapy startup Dimension Therapeutics files for $115M IPO | Cambridge gene therapy player Dimension Therapeutics just filed for a $115 million IPO – right on the heels of an FDA sanction that it begin clinical trials for its hemophilia B treatment. The company raised $65 million Series B round from ... |
| - | Gene therapy startup launches with $5M and eyes toward a better treatment for hemophilia | A newly formed gene therapy startup is taking gene delivery technology from ReGenX and a $5 million investment from Fidelity Biosciences to develop new treatments for rare diseases, starting with hemophilia. ReGenX and Fidelity Biosciences ... |